^
Association details:
| Biomarker: | EML4-ALK E13;A20 |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Detection of crizotinib-sensitive lung adenocarcinomas with MET, ALK and ROS1 genomic alterations via comprehensive genomic profiling
Excerpt:
We report 3 cases of lung adenocarcinoma; one each identified to harbor an ALK-rearrangement (EML4-ALK), ROS1-rearrangement (SDC4-ROS1) and MET-amplification by genomic profiling...The original method of detection of ALK was performed using ALK FISH and subsequently the tumor was confirmed to have EML4-ALK-E13;A20 using CGP (Table 2)...The patient tolerated crizotinib 250 mg twice daily with minimal changes in vision, gastrointestinal problems (diarrhea) and edema as adverse events. Within a month of crizotinib, his baseline cardio-pulmonary symptoms improved and he attained radiographic improvement of his cancer-related lesions.
DOI:
10.1016/j.cllc.2015.03.002
